ES2188935T3 - Polipeptido de fusion para influir sobre interacciones entre proteinas. - Google Patents

Polipeptido de fusion para influir sobre interacciones entre proteinas.

Info

Publication number
ES2188935T3
ES2188935T3 ES97919258T ES97919258T ES2188935T3 ES 2188935 T3 ES2188935 T3 ES 2188935T3 ES 97919258 T ES97919258 T ES 97919258T ES 97919258 T ES97919258 T ES 97919258T ES 2188935 T3 ES2188935 T3 ES 2188935T3
Authority
ES
Spain
Prior art keywords
proteins
interactions
influate
fusion polypeptide
polypeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97919258T
Other languages
English (en)
Inventor
Stefan Rose-John
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ROSE JOHN STEFAN
Original Assignee
ROSE JOHN STEFAN
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ROSE JOHN STEFAN filed Critical ROSE JOHN STEFAN
Application granted granted Critical
Publication of ES2188935T3 publication Critical patent/ES2188935T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)

Abstract

LA PRESENTE INVENCION TRATA DE UN CONJUGADO QUE COMPRENDE DOS POLIPEPTIDOS QUE MUESTRAN AFINIDAD MUTUA Y ESTAN UNIDOS ENTRE SI A TRAVES DE UN LINKER. LA INVENCION TRATA ADEMAS DEL EMPLEO DE UN CONJUGADO DE ESTE TIPO PARA MODIFICAR INTERACCIONES ENTRE PROTEINAS.
ES97919258T 1996-03-07 1997-03-07 Polipeptido de fusion para influir sobre interacciones entre proteinas. Expired - Lifetime ES2188935T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19608813A DE19608813C2 (de) 1996-03-07 1996-03-07 Konjugat zur Beeinflussung von Wechselwirkungen zwischen Proteinen

Publications (1)

Publication Number Publication Date
ES2188935T3 true ES2188935T3 (es) 2003-07-01

Family

ID=7787490

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97919258T Expired - Lifetime ES2188935T3 (es) 1996-03-07 1997-03-07 Polipeptido de fusion para influir sobre interacciones entre proteinas.

Country Status (9)

Country Link
US (1) US7112436B1 (es)
EP (1) EP0888384B1 (es)
JP (1) JP4301575B2 (es)
AT (1) ATE229542T1 (es)
DE (2) DE19608813C2 (es)
DK (1) DK0888384T3 (es)
ES (1) ES2188935T3 (es)
PT (1) PT888384E (es)
WO (1) WO1997032891A2 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6217858B1 (en) 1997-02-11 2001-04-17 Hadasit & Medical Research Services & Development Company, Ltd. Pharmaceutical composition for treating hepatitis B virus (HBV) infection
IL122818A0 (en) * 1997-07-10 1998-08-16 Yeda Res & Dev Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof
EP2316944A3 (en) * 2000-06-16 2011-11-02 Asterion Limited Binding agents: chimeric ligand/receptor proteins
DE10107737A1 (de) * 2001-02-16 2002-09-05 S Rose John Christian Albrecht Verwendung eines Konjugats aus IL-6 und einem IL-6 Rezeptor zur Tumortherapie
EP1499332A4 (en) * 2002-04-29 2006-12-06 Hadasit Med Res Service COMPOSITIONS AND METHODS FOR TREATING CANCER WITH A VIRAL ONCOLYTIC AGENT
EP1400587A1 (en) * 2002-09-19 2004-03-24 MainGen Biotechnologie GmbH Use of a fusion polypeptide for obtaining pluripotent non-embryonic stem cells
IL161672A0 (en) 2004-04-29 2004-09-27 Yeda Res & Dev Compositions and methods for therapy of chemotherapy-induced neuropathy
EP1598364A1 (en) * 2004-05-21 2005-11-23 AGIRx Limited Chimerical soluble hyper IL-11 receptor and use thereof
DE102004033122A1 (de) * 2004-07-08 2006-02-09 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Vorrichtung und Verfahren zur Analyse von Wechselwirkungen zwischen Biomolekülen
NZ581779A (en) 2005-05-17 2011-09-30 Univ Connecticut Composition and methods for immunomodulation in an organism comprising interleukin-15 polypeptide and interleukin-15 receptor subunit A polypeptide complex
EP2335714B1 (en) 2005-06-16 2014-02-26 Hadasit Medical Research Services And Development Ltd. A complex comprising IL-6 and soluble IL-6 receptor for use in the treatment of renal failure
EP1777294A1 (en) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
US9303080B2 (en) 2006-01-13 2016-04-05 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health Codon optimized IL-15 and IL-15R-alpha genes for expression in mammalian cells
US20090098529A1 (en) * 2006-10-16 2009-04-16 Nanhai Chen Methods for attenuating virus strains for diagnostic and therapeutic uses
AU2008269032B2 (en) 2007-06-27 2013-12-05 Novartis Ag Complexes of IL-15 and IL-15Ralpha and uses thereof
WO2009019441A2 (en) * 2007-08-03 2009-02-12 Asterion Limited Granulocyte colony stimulating factor
GB0715213D0 (en) * 2007-08-06 2007-09-12 Asterlon Ltd Igf-1
WO2009069133A2 (en) * 2007-11-28 2009-06-04 Hadasit Medical Research Services And Development Ltd. Methods for the treatment of radiation or chemotherapy-induced tissue damage
WO2009139921A2 (en) * 2008-05-16 2009-11-19 Genelux Corporation Microorganisms for preventing and treating neoplasms accompanying cellular therapy
AU2010205782A1 (en) * 2009-01-16 2011-09-08 Agirx Limited Vaccine compositions
EP2464377B1 (en) 2009-08-14 2016-07-27 The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services Use of il-15 to increase thymic output and to treat lymphopenia
WO2011151716A1 (en) 2010-06-04 2011-12-08 Lupin Limited Process for the purification of recombinant human il-11
JP6280031B2 (ja) 2012-03-29 2018-02-14 中外製薬株式会社 抗ｌａｍｐ５抗体およびその利用
EP2986312B1 (en) 2013-04-19 2021-12-15 Cytune Pharma Cytokine derived treatment with reduced vascular leak syndrome
EP2915569A1 (en) 2014-03-03 2015-09-09 Cytune Pharma IL-15/IL-15Ralpha based conjugates purification method
EP2992898A1 (en) 2014-09-04 2016-03-09 Klinikum rechts der Isar der Technischen Universität München T-cell adjuvant and its use for therapeutic or prophylactic vaccination
CN110055224B (zh) * 2019-04-03 2023-06-30 深圳市体内生物医药科技有限公司 一种基因修饰的免疫细胞及其制备方法和应用
EP3875111A1 (en) 2020-03-05 2021-09-08 Poznan University Of Medical Sciences Stem cell cancer vaccine composition

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260203A (en) * 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
GB9324807D0 (en) 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
DK0776339T4 (da) * 1994-07-29 2010-05-25 Sunol Molecular Corp MHC-komplekser og anvendelser deraf

Also Published As

Publication number Publication date
WO1997032891A2 (de) 1997-09-12
DK0888384T3 (da) 2003-03-24
DE59708952D1 (de) 2003-01-23
US7112436B1 (en) 2006-09-26
JP2000506014A (ja) 2000-05-23
JP4301575B2 (ja) 2009-07-22
DE19608813A1 (de) 1997-09-18
EP0888384B1 (de) 2002-12-11
PT888384E (pt) 2003-04-30
DE19608813C2 (de) 1998-07-02
WO1997032891A3 (de) 1998-02-05
ATE229542T1 (de) 2002-12-15
EP0888384A2 (de) 1999-01-07

Similar Documents

Publication Publication Date Title
ES2188935T3 (es) Polipeptido de fusion para influir sobre interacciones entre proteinas.
WO2000018921A3 (en) Synthetic peptides having fgf receptor affinity
BR0212256A (pt) Proteìnas de fusão de transferrina modificadas
ES2149149T1 (es) Proteinas de fijacion de interleuquina-18, su preparacion y utilizacion.
EA200100216A1 (ru) Композиции на основе слитого белка ов и способы их применения
WO1999002711A3 (en) Fusion proteins with an immunoglobulin hinge region linker
ATE533784T1 (de) Lösliche, einzelkettige proteine des t- zellrezeptors
PT1121382E (pt) Proteinas de fusao do interferao beta e as respectivas utilizacoes
PL336306A1 (en) Proteinous fusions of tgf-beta ii type receptor with a constant immunoglobulin area
DK1088084T3 (da) Erythropoietin analog-humant serumalbumin fusionsprotein
ES2077666T3 (es) Proteina de union a fibronectina y su preparacion.
DK1017715T3 (da) Kimært polypeptid der omfatter fragment B af shiga-toksin og peptider af terapeutisk interesse
ES2091824T3 (es) Proteina recombinante de fusion toxina anticuerpo.
ES543938A0 (es) Un procedimiento para preparar un gen fusionado que codifica una proteina hibrida susceptible de marcado y empleo en diagnosis.
ES2123973T3 (es) Afamina: una proteina similar a la seroalbumina humana.
BR9709900A (pt) Proteìnas de ligacão de proteìnas de prìons e usos das mesmas.
PT625157E (pt) Epitopes p1a1 e p1a2 da gpiiia da plaqueta sua preparacao e utilizacao
DK0506923T3 (da) Et collagenbindende protein samt fremstilling deraf
EA200000875A1 (ru) Белки, взаимодействующие с каспазой-8
EA200400392A1 (ru) Связывающий каспазу-8 белок, его получение и применение
PT929299E (pt) 1,2,3,4-tetra-hidro-2-dibenzofuranaminas e 2-aminociclo-hepta ¬b| benzofuranos substituidos
DK0938555T3 (da) Konstruktioner og komplekser af cyclin E
IT1291053B1 (it) Snodo sferico.
WO2001085100A3 (en) Vasodilator-thrombolytic fusion proteins and conjugates
DK1127133T3 (da) Polypeptid, der formidler cellegennemtrængelighed